AR-12286
Phase 2Small molecule
AR-12286 is one of 3 small molecule programs targeting Exfoliation Syndrome. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Exfoliation Syndrome
#DrugCompanyPhaseTrials
1Travatan
NovartisApproved
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
AR-12286
AAerie Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AR-12286. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAerie Pharmaceuticals